Calls
2
Zach Reitano
Co-Founder and CEO, Ro
Win Rate
0.0%
return
-17.0%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 06
$34.58
-9.7%
Zach expects the oral GLP-1 launch to massively expand the total GLP-1 market rather than just cannibalize injectables. The key driver is the large pool of GLP-1-curious patients—tens of millions who have been on the sidelines—plus lower $149 pricing, pill convenience, same weight-loss efficacy, and reduced stigma around prescription weight loss.
Thematic ETFs
Long
Jan 06
$57.19
-24.2%
Ro is seeing tremendous demand for Novo Nordisk's oral Wegovy GLP-1 pill, which launched as the first direct-to-consumer GLP-1 on day one. The pill starts at $149 for the first dose versus roughly $1,300 previously, matches injectable weight-loss efficacy, and enables diagnosis-to-delivery in 48 hours or less, making it a major positive for Novo Nordisk's obesity franchise.
GLP-1 / Obesity
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Zach Reitano has 2 trade ideas tracked on Buzzberg across 2 tickers since January 2026. Most covered: NVO, OZEM, ORAL GLP-1 DRUGS.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
